Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050855 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
A Phase 2 study of Hemoglobinopathies and Immunodeficiencies, sponsored by Children's Hospital of Philadelphia.
- Active
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT01050855 is a Phase 2 study of Hemoglobinopathies and Immunodeficiencies that is active but no longer recruiting, run by Children's Hospital of Philadelphia. The registered enrollment target is 75 participants, below the 1,799-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01050855, a Phase 2 study of Hemoglobinopathies and Immunodeficiencies, is active but no longer recruiting, sponsored by Children's Hospital of Philadelphia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently, reduced intensity conditioning (RIC) regimens have been used for both adult patients with leukemias and pediatric patients with non-malignant diseases. These regimens are better tolerated, resulting in less transplant related morbidity and mortality. Stable mixed chimerism, while insufficient for eradication of leukemias, may be sufficient to cure patients with non-malignant diseases.
Conditions Studied
Interventions
- DRUG RIC: Distal Campath
- DRUG RIC:Intermediate Campath
- DRUG RIC: Mini Busulfan
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2008-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01050855
The ClinicalTrials.gov registry entry for NCT01050855 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,799-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (96% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 3 interventions - of which RIC: Distal Campath is the first listed.
NCT01050855 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01050855 about?
NCT01050855 is a clinical study titled "Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders". This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently...
What is the current status of trial NCT01050855?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2008-01. Estimated completion is 2026-12.
What conditions does trial NCT01050855 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Immunodeficiencies, Non Malignant Diseases.
What interventions are being tested in trial NCT01050855?
The interventions under investigation include: RIC: Distal Campath (DRUG), RIC:Intermediate Campath (DRUG), RIC: Mini Busulfan (DRUG).
Who is sponsoring clinical trial NCT01050855?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01050855 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
RECRUITING · Phase 2
-
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
COMPLETED · Phase 2
-
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RECRUITING · Phase 1
-
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
RECRUITING · NA
-
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.